Oxytocin Administration During Cesarean Section

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall. This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy The guidelines of the Royal College of Obstetricians and Gynaecologists on caesarean section recommend a slow intravenous bolus dose of 5 IU of oxytocin after delivery of the infant. Intravenous oxytocin has a short half life (4-10 minutes); therefore the potential advantage of an oxytocin infusion at caesarean section is in maintaining uterine contractility throughout the surgical procedure and immediate postpartum period, when most primary haemorrhage occurs

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Primigravida or multigravida

• Term (37 - 42 weeks),

• Singleton pregnancies

• Booked for elective caesarean section.

• Accepting to participate in the study.

Exclusion Criteria:

• • Medical disorders involving the heart, liver, kidney or brain.

• Diabetes mellitus and hypertension.

• Blood disorders (e.g. coagulopathies, thrombocytopenia)

• Patients requiring blood transfusion due to anemia.

• Risk factors for uterine atony e.g. macrosomia, polyhydramnios and multiple pregnancy.

• Previous 2 or more cesarean section

• Placenta previa or placental abruption

• Previous major obstetric haemorrhage (>1000 ml) in previous deliveries.

• Known fibroid or adenomyosis.

• Women who received anticoagulant therapy.

• Severe preeclampsis.

• Uterine anomalies.